>IYO, is this bona fide differentiation… or mostly spin?<
It may be mostly spin. ESC+ suppose to increase liver delivery/uptake (so, lower system dose needed for the same therapeutic effects), but how will this reduce systemic *LIVER* toxicity is not clear (ar to understand easily). I did not looked closely in chemistry modification. Maybe way to go is observing similar enhancement for other target???
Maybe ESC+ help when target tissue is not easily available???
Market Data 
Markets 
AI
